CEDARVILLE Engineering Group, LLC, (CEDARVILLE) and Rockland Immunochemicals, Inc., today announced a research collaboration designed to explore the development of innovative applications in 3D bioprinting that will advance life science research and accelerate the drug discovery process. Interest in 3D bioprinting has emerged in recent years. Applications for 3D bioprinting include drug screening, precision and regenerative medicine, food products and biosensors. The project is expected to leverage the expertise CEDARVILLE has in 3D modeling and printing, and the insight Rockland has in developing cutting-edge reagents and cell culture processes critical to novel biotechnologies.
“Every day, we help determine the planning and development of roadways, bridges, utility expansion and industrial or commercial sites. In that macro context, we have developed processes to create 3D scalable models with precision and accuracy to fit the workflows in that paradigm.” says April M. Barkasi, PE, President and CEO of CEDARVILLE. “This project...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!